No products
Data sheet
| Assay time | 4.5 hours |
| Assay Range | 0.5 - 32 ng/mL |
| Storage | Store components based on instruction in the manual. |
| Background | Zika virus (ZIKV) is an arthropod-borne flavivirus closely related to dengue, yellow fever and West Nile viruses, which has caused an emerging epidemic in the Americas, the Caribbean, and the Pacific regions. While ZIKV is spread primarily through the bite of an infected Aedes species mosquito, cases of sexual transmission have also been reported. ZIKV infection is associated with severe illness in humans including microcephaly and birth defects in newborns and Guillain-Barré syndrome in adults. Consequently, ZIKV infection poses significant threats to global health. Non-structural 1 (NS1) protein has emerged as promising targets as antibodies that do not bind the virion are unlikely to enhance disease. In a recent study of four patients infected by ZIKV, 34.4% of virus-specific mAbs target the NS1 protein8. This immunogenic glycoprotein plays an essential role in viral RNA replication and immune evasion. The NS1 protein is initially translated as a monomer, becomes glycosylated in the ER and subsequently forms a dimer that can potentially traffic to multiple distinct locations within the cell15. The NS1 protein of many flaviviruses is known to associate with the viral replication complex on the surface of the endoplasmic reticulum membrane, associate with the plasma membrane by a glycosylphosphatidylinositol linker, exit cells to form a lipophilic hexamer, and potentially bind to uninfected cells via glycosaminoglycan interactions. NS1 is required for viral replication inside cells and is also secreted into the extracellular space as a hexameric lipoprotein particle, which is involved in immune evasion and pathogenesis by interacting with components from both the innate and adaptive immune systems. NS1 is the major antigenic marker for viral infection. To date, no clinically approved vaccines or therapeutics are available to prevent and control of Zika virus infection. |
| Assay principle | The Zika virus NS1 antigen ELISA Kit is based on standard sandwich enzyme-linked immunosorbent assay technology. Mouse anti-Zika virus NS1 antigen specific antibody has been pre-coated onto 96-well plate. Zika virus NS1 antigen present in the standards/ samples bind to the capture antibody. Subsequently, biotinylated goat anti-Zika virus NS1 antigen detection antibody is added to form an Ab-Ag-Ab sandwich. After a washing step, streptavidin-HRP is added and the unbound conjugate is removed with wash buffer. Next, addition of HRP substrate, TMB, results in the production of a blue colored product that changes to yellow after the addition of acidic Stop Solution. The density of yellow color is directly proportional to the amount of Zika virus NS1 antigen captured on plate. |
| Related Products | Zika Virus Envelope (Env) Antigen ELISA Kit, NB-400927 Zika Virus IgG ELISA Kit NB-400926G Zika Virus IgM ELISA Kit NB-400926M |
| UniProt ID | A0A024B7W1 |
More info
The Zika virus NS1 antigen ELISA Kit is based on standard sandwich enzyme-linked immunosorbent assay technology. Mouse anti-Zika virus NS1 antigen specific antibody has been pre-coated onto 96-well plate. Zika virus NS1 antigen present in the standards/ samples bind to the capture antibody. Subsequently, biotinylated goat anti-Zika virus NS1 antigen detection antibody is added to form an Ab-Ag-Ab sandwich.
Components:
1. Zika virus NS1 antigen standard: 2 vials
2. 96-well plate pre-coated with
anti-Zika virus NS1 antigen Ab: 1
3. Sample Diluent buffer : 12 ml × 2
4. Detection antibody: 1 vial, dilution 1:100
5. Streptavidin-HRP: 1 vial dilution 1:100
6. Antibody Diluent buffer: 12 ml
7. Streptavidin HRP diluent buffer: 12 ml
8. Chromogen Solution A: 6 ml
9. Chromogen Solution B: 6 ml
10. Stop Solution: 6 ml
11. 20 × Wash Buffer: 25 ml
12. Plate sealers 2
13. Package insert 1
Related products: